Exploring β-carboline hybrids and their derivatives: A review on synthesis and anticancer efficiency

IF 5.9 2区医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2025-02-17 DOI:10.1016/j.ejmech.2025.117412

Nur Fatihah Sulaiman , Siti Zafirah Zulkifli , Aimi Suhaily Saaidin , Ravindar Lekkala , Nurul Izzaty Hassan , Noor Hidayah Pungot

{"title":"Exploring β-carboline hybrids and their derivatives: A review on synthesis and anticancer efficiency","authors":"Nur Fatihah Sulaiman , Siti Zafirah Zulkifli , Aimi Suhaily Saaidin , Ravindar Lekkala , Nurul Izzaty Hassan , Noor Hidayah Pungot","doi":"10.1016/j.ejmech.2025.117412","DOIUrl":null,"url":null,"abstract":"<div><div>β-Carboline is a crucial compound in medicinal chemistry known for its versatile pharmacological activities. Recent research has focused on hybrid molecules incorporating a β-carboline scaffold linked to other pharmacophore moieties. These hybrid compounds have demonstrated diverse therapeutic properties, including anticancer, antianxiety, antimalarial, antidepressant, anti-inflammatory, antileishmanial, and antioxidant effects. This review highlights studies conducted from 2014 to the present with a particular emphasis on the development of β-carboline hybrid compounds and their derivatives as potent anticancer agents. The structure-activity relationship (SAR) analysis reveals that these hybrids exhibit significant cytotoxicity against various cancer cell lines. This review aims to inspire further research into the novel synthesis and evolution of β-carboline hybrids and their derivatives, potentially leading to new therapeutic advancements.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"288 ","pages":"Article 117412"},"PeriodicalIF":5.9000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425001771","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

β-Carboline is a crucial compound in medicinal chemistry known for its versatile pharmacological activities. Recent research has focused on hybrid molecules incorporating a β-carboline scaffold linked to other pharmacophore moieties. These hybrid compounds have demonstrated diverse therapeutic properties, including anticancer, antianxiety, antimalarial, antidepressant, anti-inflammatory, antileishmanial, and antioxidant effects. This review highlights studies conducted from 2014 to the present with a particular emphasis on the development of β-carboline hybrid compounds and their derivatives as potent anticancer agents. The structure-activity relationship (SAR) analysis reveals that these hybrids exhibit significant cytotoxicity against various cancer cell lines. This review aims to inspire further research into the novel synthesis and evolution of β-carboline hybrids and their derivatives, potentially leading to new therapeutic advancements.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

β-羰基杂合体及其衍生物的研究进展及其抗癌效果

β-胭脂碱是一种重要的药物化学化合物，以其多种药理活性而闻名。最近的研究集中在结合β-碳碱支架与其他药效团部分连接的杂交分子上。这些混合化合物已显示出多种治疗特性，包括抗癌、抗焦虑、抗疟疾、抗抑郁、抗炎、抗利什曼原虫和抗氧化作用。本文综述了2014年至今的研究成果，特别强调了β-碳碱杂化化合物及其衍生物作为强效抗癌剂的发展。构效关系（SAR）分析表明，这些杂交种对多种癌细胞具有显著的细胞毒性。这篇综述的目的是激发对β-羰基杂合体及其衍生物的新合成和进化的进一步研究，可能导致新的治疗进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.